Chinese Biosimilar Boom Is Heralded By First Approval
Executive Summary
Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.
You may also be interested in...
Henlius’ Rituximab Results Bolster RA Ambitions In China
Shanghai Henlius Biotech has taken its groundbreaking Chinese rituximab biosimilar a step closer to securing a key rheumatoid arthritis indication.
Henlius Capitalizes On Biosimilar Launches
Henlius has announced plans to expand its global footprint and bolster its manufacturing capacity after seeing its sales shoot up in 2020 based on three new launches.
Henlius Seeks To Add RA Indication To Chinese Rituximab
Shanghai Henlius Biotech has filed with China’s NMPA to add a rheumatoid arthritis indication to its HLX01 approved rituximab biosimilar, despite the originator not being approved for RA in China.